
Sign up to save your podcasts
Or
How do you counsel patients eligible for the RSV vaccines? What do the results of the RENOIR and AReSVi trials tell us and how do they compare? How should we interpret vaccine trials in the first place? Tune in to the fourth episode of Beyond Journal Club, a new series brought to you by Core IM in collaboration with NEJM Group.
Sponsor: Pathway FREE evidence-based clinical decision support app. Guideline summaries, interactive algorithms, landmark trials & more
Show Notes & Transcript
Time Stamps:
(02:30) | Epidemiology of RSV
(03:46) | Development of RSV vaccine
(05:55) | Vaccine trial design
(12:22) | ARESVI and RENOIR Trials
(18:18) | Who should we recommend the RSV vaccine to?
(19:50) | What don’t we know?
Tags: IMCore, CoreIM, primary care, infectious disease, nurse practitioner, pharmacist, physician assistant
4.8
10651,065 ratings
How do you counsel patients eligible for the RSV vaccines? What do the results of the RENOIR and AReSVi trials tell us and how do they compare? How should we interpret vaccine trials in the first place? Tune in to the fourth episode of Beyond Journal Club, a new series brought to you by Core IM in collaboration with NEJM Group.
Sponsor: Pathway FREE evidence-based clinical decision support app. Guideline summaries, interactive algorithms, landmark trials & more
Show Notes & Transcript
Time Stamps:
(02:30) | Epidemiology of RSV
(03:46) | Development of RSV vaccine
(05:55) | Vaccine trial design
(12:22) | ARESVI and RENOIR Trials
(18:18) | Who should we recommend the RSV vaccine to?
(19:50) | What don’t we know?
Tags: IMCore, CoreIM, primary care, infectious disease, nurse practitioner, pharmacist, physician assistant
321 Listeners
250 Listeners
502 Listeners
693 Listeners
280 Listeners
3,330 Listeners
195 Listeners
713 Listeners
517 Listeners
360 Listeners
254 Listeners
425 Listeners
257 Listeners
367 Listeners
235 Listeners